Prana candidate reduces Abeta levels

By Dylan Bushell-Embling
Thursday, 10 July, 2008

Key findings from Prana Biotechnology's [ASX: PBT] preclinical research of its proprietary PBT2 Alzheimer's drug have been published in the prestigious scientific journal Neuron.

The article, "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Abeta," can be viewed on-line by Neuron subscribers.

PBT2 was found to rapidly and profoundly improve cognition in transgenic mice, by substantially reducing the amount of Abeta - amyloid beta, the main constituent of Alzheimer's plaques - in the brain over a nine-month period.

The findings will be presented at the 11th International Conference on Alzheimer's Disease, to be held in Chicago at the end of the month.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd